CN102395363A - Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物 - Google Patents

Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物 Download PDF

Info

Publication number
CN102395363A
CN102395363A CN2010800151213A CN201080015121A CN102395363A CN 102395363 A CN102395363 A CN 102395363A CN 2010800151213 A CN2010800151213 A CN 2010800151213A CN 201080015121 A CN201080015121 A CN 201080015121A CN 102395363 A CN102395363 A CN 102395363A
Authority
CN
China
Prior art keywords
fibrosis
inhibitors
kinases
kinase
pulmonary fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800151213A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·哈迪
罗伯特·柯克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cascadian Therapeutics Inc
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Publication of CN102395363A publication Critical patent/CN102395363A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800151213A 2009-04-09 2010-04-08 Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物 Pending CN102395363A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16790509P 2009-04-09 2009-04-09
US61/167,905 2009-04-09
US23574009P 2009-08-21 2009-08-21
US61/235,740 2009-08-21
PCT/US2010/030420 WO2010118250A2 (en) 2009-04-09 2010-04-08 Methods and compositions of pi-3 kinase inhibitors for treating fibrosis

Publications (1)

Publication Number Publication Date
CN102395363A true CN102395363A (zh) 2012-03-28

Family

ID=42936877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800151213A Pending CN102395363A (zh) 2009-04-09 2010-04-08 Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物

Country Status (10)

Country Link
US (1) US20120046333A1 (https=)
EP (1) EP2416771A4 (https=)
JP (1) JP2012523429A (https=)
KR (1) KR20120018761A (https=)
CN (1) CN102395363A (https=)
AU (1) AU2010234360A1 (https=)
BR (1) BRPI1015940A2 (https=)
CA (1) CA2754343A1 (https=)
MX (1) MX2011010631A (https=)
WO (1) WO2010118250A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727478A (zh) * 2012-06-14 2012-10-17 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治肾纤维化药物中的应用
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
JP2022065212A (ja) * 2019-02-28 2022-04-27 国立大学法人京都大学 組織線維化による疾患の予防又は治療のための医薬
WO2020201073A1 (en) * 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
EP4259207A4 (en) * 2020-12-10 2025-02-26 Children's Hospital Medical Center IMPROVED NANOPARTICLE RELEASE SYSTEMS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101180055A (zh) * 2005-05-27 2008-05-14 拜耳医药保健股份公司 用于治疗疾病的包含二芳基脲的组合治疗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
US7723375B2 (en) * 2004-07-09 2010-05-25 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Metabolites of wortmannin analogs and methods of using the same
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101180055A (zh) * 2005-05-27 2008-05-14 拜耳医药保健股份公司 用于治疗疾病的包含二芳基脲的组合治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《Molecular Biology of the Cell》 20040630 Xu Shi-Wen，et al Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts 2707-2719 7-11 第15卷, 第6期 *
XU SHI-WEN，ET AL: "Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts", 《MOLECULAR BIOLOGY OF THE CELL》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727478A (zh) * 2012-06-14 2012-10-17 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治肾纤维化药物中的应用
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途

Also Published As

Publication number Publication date
WO2010118250A3 (en) 2011-03-31
AU2010234360A1 (en) 2011-09-29
EP2416771A2 (en) 2012-02-15
EP2416771A4 (en) 2012-10-31
BRPI1015940A2 (pt) 2016-04-19
MX2011010631A (es) 2012-01-20
WO2010118250A2 (en) 2010-10-14
CA2754343A1 (en) 2010-10-14
JP2012523429A (ja) 2012-10-04
KR20120018761A (ko) 2012-03-05
US20120046333A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
CN102395363A (zh) Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
Yu et al. Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect
JP2008013577A (ja) 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
EP3352759A1 (en) Treatment of neurodegenerative diseases
Son et al. Ilimaquinone inhibits neovascular age-related macular degeneration through modulation of Wnt/β-catenin and p53 pathways
JP2023518375A (ja) 治療方法
JP2021528392A (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるアシルスルホンアミド
Guyonnet et al. Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury
US10172914B2 (en) Combination
Miyata et al. Renoprotective effects of direct renin inhibition in glomerulonephritis
WO2018196870A1 (zh) 靶向前列腺素e2及其受体的药物与应用
US20150284393A1 (en) Methods for treating eye disorders
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
US20260042816A1 (en) Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah)
Liu et al. Inhaled B7 alleviates bleomycin-induced pulmonary fibrosis in mice
JP2002154985A (ja) 眼疾患治療剤
DE69637316T2 (de) Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
WO2023230593A1 (en) Ptp1b inhibitors for treating lung injury
HK40069641A (en) Compositions and methods for treating pterygium
EA051681B1 (ru) Модуляторы щелевых контактов и их применение для лечения возрастной макулярной дегенерации
WO2014065370A1 (ja) 肺高血圧症治療剤
Riu et al. Serine/arginine rich protein kinase-1 (SRPK1) inhibition for the treatment of diabetic 1 retinopathy 2 3 Naseeb K Malhi1, Claire L Allen1, Elizabeth Stewart2, Katherine L Horton1, Federica 4
HK1256602B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120328